Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Income from Continuing Operations (2021 - 2025)

Historic Income from Continuing Operations for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to -$308000.0.

  • Verrica Pharmaceuticals' Income from Continuing Operations rose 9865.26% to -$308000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.3 million, marking a year-over-year increase of 7147.24%. This contributed to the annual value of -$73.9 million for FY2024, which is 1035.07% down from last year.
  • Latest data reveals that Verrica Pharmaceuticals reported Income from Continuing Operations of -$308000.0 as of Q3 2025, which was up 9865.26% from -$393000.0 recorded in Q2 2025.
  • Verrica Pharmaceuticals' Income from Continuing Operations' 5-year high stood at $1.5 million during Q3 2022, with a 5-year trough of -$24.8 million in Q3 2023.
  • For the 5-year period, Verrica Pharmaceuticals' Income from Continuing Operations averaged around -$11.0 million, with its median value being -$10.2 million (2022).
  • As far as peak fluctuations go, Verrica Pharmaceuticals' Income from Continuing Operations soared by 11180.92% in 2022, and later crashed by 173379.54% in 2023.
  • Verrica Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$9.5 million in 2021, then skyrocketed by 37.89% to -$5.9 million in 2022, then crashed by 316.02% to -$24.6 million in 2023, then soared by 45.01% to -$13.6 million in 2024, then surged by 97.73% to -$308000.0 in 2025.
  • Its Income from Continuing Operations was -$308000.0 in Q3 2025, compared to -$393000.0 in Q2 2025 and -$10.0 million in Q1 2025.